Recent serious developments and flare-ups between the US and China send chills in investor community, raising grave concerns and increasing uncertainty over cross-border deals and fund flows, amid an ongoing global health crisis.

While COVID-19 closed the window for most initial public offerings late in the first quarter, drug developers continue to launch IPOs, generating an average return of nearly 21% year-to-date.

Genexine’s recent M&A activity and foreign partnerships underscore its strategy on pipeline innovative therapeutics and biobetters as well as preparations to secure future growth engines, the Korean firm's vice-president tells Scrip in an interview.

Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.